Key facts
- Sola Biosciences’s last known valuation is $18.2M (Sep 2021).
- It has raised $35.5M; the latest was Later Stage VC ($10.0M) in Jan 2025.
- Notable investors include The University of Tokyo Edge Capital, ABI LAB, Curie.Bio, Eisai, Eisai Innovation — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Sola Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Sola Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sola Biosciences
Developer of transformative gene therapies designed to treat conformational diseases. The company uses its proprietary chaperone platform technology to develop therapeutics for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Huntington's disease (HD), by selectively reducing the abnormal disease-causing proteins that form toxic clumps in the neuron cells of patients, enabling patients to get permanent treatment for neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- Natick, MA, United States
- Founded
- 2016
- Employees
- 5
- Website
- sola-bio.com/
- Ownership
- Privately Held (backing)
Sola Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sola Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sola Biosciences in its N-PORT filings yet. We sweep new filings monthly.